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a b s t r a c t
Background: Since the re-discovery of sulforaphane in 1992 and the recognition of the bioactivity of this
phytochemical, many studies have examined its mode of action in cells, animals and humans. Broccoli,
especially as young sprouts, is a rich source of sulforaphane and broccoli-based preparations are now
used in clinical studies probing efﬁcacy in health preservation and disease mitigation. Many putative
cellular targets are affected by sulforaphane although only one, KEAP1-NRF2 signaling, can be considered
a validated target at this time. The transcription factor NRF2 is a master regulator of cell survival re-
sponses to endogenous and exogenous stressors.
Scope and Approach: This review summarizes the chemical biology of sulforaphane as an inducer of NRF2
signaling and efﬁcacy as an inhibitor of carcinogenesis. It also provides a summary of the current ﬁndings
from clinical trials using a suite of broccoli sprout preparations on a series of short-term endpoints
reﬂecting a diversity of molecular actions.
Key Findings and Conclusions: Sulforaphane, as a pure chemical, protects against chemical-induced skin,
oral, stomach, colon, lung and bladder carcinogenesis and in genetic models of colon and prostate
carcinogenesis. In many of these settings the antitumorigenic efﬁcacy of sulforaphane is dampened in
Nrf2-disrupted animals. Broccoli preparations rich in glucoraphanin or sulforaphane exert demonstrable
pharmacodynamic action in over a score of clinical trials. Measures of NRF2 pathway response and
function are serving as guideposts for the optimization of dose, schedule and formulation as clinical trials
with broccoli-based preparations become more commonplace and more rigorous in design and
implementation.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Development of proactive prevention programs, e.g., preventive,
predictive, personalized and participatory (“P4”), are emerging as
important elements to control a number of chronic, degenerative
diseases. The transformation of cancer prevention through
personalized or precision medicine is a prime example of current
opportunity (Kensler et al., 2016), although any one of the P4 ele-
ments alone will not be sufﬁcient. Within the context of cancer,
much of the expanding global burden will occur in the developing
and recently developed countries. Many in these regions, and
arguably most regions, will have neither access nor ability to afford
the latest generation of molecular-targeted pharmaceuticals. By
contrast, implementation programs for tobacco control, vaccina-
tion, screening, as well as public health programs promoting
physical activity and consumption of healthier diets will have
greater impact on population health broadly and cancer prevention
speciﬁcally. Access to local foodstuffs containing bioactive phyto-
chemicals may offer a frugal or “green” (Fahey, Talalay, & Kensler,
2012a) means for accelerating disease prevention. Appreciation of
the mechanisms of the action of such phytochemicals will facilitate
the utilization of indigenous protective foods or perhaps guide the
introduction of culturally appropriate new foods into their diets.
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Based on ﬁndings from epidemiology studies suggesting that
frequent consumption of cruciferous vegetables was associated
with lower incidence of multiple tumor types, Talalay and col-
leagues screened extracts of these and other vegetables for bioac-
tive molecules for efﬁcacy and potency in the induction of enzymes
known to detoxify carcinogens (Zhang, Kensler, Cho, Talalay &
Posner, 1992), a process now known to involve NRF2 signaling.
Sulforaphane [1-isothiocyanato-4-(methylsulﬁnyl)butane] (Fig. 1) a
phytochemical belonging to a large chemical family of iso-
thiocyanates was thus identiﬁed. Sulforaphane is formed from the
stable, water-soluble precursor glucosinolate termed glucor-
aphanin in a variety of cruciferous vegetables including broccoli,
Brussels sprouts, cauliﬂower, and cabbage by myrosinase, a b-thi-
oglucoside glucohydrolase (EC 3.2.1.147), during damage of plant
integrity or by hydrolysis by uncharacterized b-thioglucosidases of
the gut microﬂora (Shapiro, Fahey, Wade, Stephenson, & Talalay,
2001). During glucoraphanin hydrolysis, glucose is liberated and
an unstable aglycone is formed that spontaneously rearranges to
metabolites such as sulforaphane (Fig. 1). At high or neutral pH,
sulforaphane will be the primary product of glucoraphanin hy-
drolysis. In contrast, at acidic pH, or in the presence of Fe2þ, with
the enzyme epithiospeciﬁer protein, the production of a nitrile,
which is less bioactive, will be favored (Hayes, Kelleher, &
Eggleston, 2008). In mammals, glucoraphanin is also taken up
from the gut to the liver where it is interconverted to its reduced
glucosinolate analog, glucoerucin, as is sulforaphane to its corre-
sponding reduced isothiocyanate analog, erucin [1-isothiocyanato-
4-(methylthio)butane] (Bheemreddy & Jeffery, 2007; Melchini &
Traka, 2010). The highest concentrations of glucosinolates are
typically found in reproductive organs of the plant, including
dormant and germinating seeds, and developing inﬂorescences,
followed by young leaves, roots, and mature leaves, which is
consistent with the function of glucosinolate-myrosinase system as
defensive mechanism in the plant (Brown, Tokuhisa, Reichelt, &
Gershenzon, 2003). Three-day-old broccoli sprouts contain
10e100 times higher levels of glucoraphanin than do mature
broccoli (Fahey, Zhang, & Talalay, 1997). With the virtues of, safety,
effectiveness, feasibility and low cost, sulforaphane in the milieu of
broccoli (especially broccoli sprout and seed preparations) has
attracted extensive interest as a potential preventive agent in
humans.
The pharmacokinetics of sulforaphane and glucoraphanin, as
either pure phytochemical studied in animals (Cornblatt et al.,
2007; Hu et al., 2004), or in a variety of plant matrices in clinical
studies (Egner et al., 2011; Fahey et al., 2012b, 2016; Shapiro et al.,
2001), have been well characterized. Sulforaphane is readily
absorbed in humans and is rapidly eliminated. Upwards of 70% of
an administered dose of sulforaphane can be recovered as thiol
conjugates in the urine; the biological half-life is only a few hours.
By contrast, glucoraphanin has poor bioavailability, with only about
10% of an administered dose being recovered as thiol conjugates of
sulforaphane in urine. The elimination phase is also longer,
reﬂecting a poor, slow and highly variable conversion of the glu-
cosinolate to isothiocyanate in the absence of plant myrosinase. As
a consequence, recent preparations for use in clinical studies
feature both plant based sources for glucoraphanin and myrosinase
(Fahey et al., 2015). Despite a near quarter century since the (re)
discovery of sulforaphane (Zhang et al., 1992), studies on the
pharmacodynamic actions of sulforaphane in humans have been
quite limited. This point stands in stark contrast to the many
hundreds of publications probing mechanisms of action in cell
culture and animal models. As reviewed elsewhere, dozens of tar-
gets and pathways have been identiﬁed as potential mediators of
the chemoprotective actions of sulforaphane (Brown & Hampton,
2011; Hayes et al., 2008; Zhang, 2012): few have undergone
serious validation. Two key approaches for target validation arise
from the questions: Does genetic disruption of the target alter
sensitivity to carcinogenesis or other disease states in animal
models? Does genetic disruption of the target abolish or attenuate
the chemopreventive efﬁcacy of candidate agents, such as sulfo-
raphane? While not dismissing many of these actions as of limited
importance, the NRF2 pathway, as detailed in this review, stands
Fig. 1. The myrosinase reaction and the interconversion of sulforaphane and erucin. The glucosinolates glucoraphanin and glucoerucin are hydrolyzed by b-thioglucosidases
(myrosinases) to give unstable aglycones and liberate glucose. Depending on the reaction conditions, a variety of reactive products can be formed, the most common of which are
the isothiocyanates (sulforaphane and erucin) and their corresponding nitriles. In mammals, glucoraphanin is also taken up from the gut to the liver where it is interconverted to its
reduced analog, glucoerucin, as is sulforaphane to erucin. R1 ¼ 4-(methylsulﬁnyl)butane; R2 ¼ 4-(methylthio)butane.
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alone as a validated target for the activity of sulforaphane. Although
unlikely to be of unilateral importance, measures of pathway
response and function can serve as guideposts for the optimization
of dose, schedule and formulation as clinical trials with broccoli-
based preparations become more commonplace and more
rigorous in design and implementation.
2. KEAP1-NRF2 signaling: a molecular target for sulforaphane
The most characteristic feature of sulforaphane is its high
chemical reactivity due to the electrophilicity of the central carbon
of the isothiocyanate (dN]C]S) group. The isothiocyanate group
reacts readily with sulfur-, nitrogen-, and oxygen-centered nucle-
ophiles [reviewed in (Mi, Di Pasqua & Chung, 2011; Zhang, 2012)].
Most common in cells is the reversible reaction of isothiocyanates
with cysteine residues in proteins and glutathione, leading to the
formation of thiocarbamate products, which are subsequently
metabolized by the mercapturic acid pathway (Fig. 2). Irreversible
alkylation reactions of isothiocyanates with the a-amino groups in
N-terminal residues of proteins, with the ε-amino groups of lysine,
or even with secondary amines, such as proline, are also possible,
and the products of these reactions are known as thioureas (Kumar
& Sabbioni, 2010; Nakamura, Kawaii, Kitamoto, Osawa, & Kato,
2009). In theory, the isothiocyanates can also react with hydroxyl
group-containing amino acid residues (e.g., tyrosine), although this
probably does not occur under physiological conditions.
Targeting KEAP1. Cysteine residues with low pKa values are
especially reactive with isothiocyanates. At physiological pH, such
cysteines exist as thiolate anions that are primed for nucleophilic
attack on the electrophilic substrate. Upon entry into the cell, sul-
foraphane chemically reacts with Kelch-like ECH associated protein
1 (KEAP1) (Itoh et al., 1999), a protein endowed with a number of
reactive cysteine residues which function as sensors for numerous
oxidants and electrophiles (termed inducers), including the iso-
thiocyanates (Dinkova-Kostova, Holtzclaw, & Kensler, 2005;
Dinkova-Kostova, Kostov, & Canning, 2016). KEAP1 is a dimeric
multidomain 624-amino acid protein that serves as a substrate
adaptor for a Cullin3-based Cullin-RING E3 ubiquitin ligase (CRL)
multisubunit protein complex. Based on its amino acid sequence,
KEAP1 has ﬁve distinct domains: (i) an N-terminal region (NTR,
amino acids 1e49), (ii) a Broad complex, Tramtrack, and Bric a brac
(BTB) domain (amino acids 50e179), through which KEAP1 forms a
homodimer and also interacts with Cullin3, (iii) an intervening
region (IVR, also known as BACK domain, amino acids 180e314),
which is especially cysteine-rich and contains 8 cysteine residues
among its 134 amino acids, (iv) a Kelch domain, comprising six
Kelch motifs (amino acids 315e359, 361e410, 412e457, 459e504,
506e551, and 553e598), through which KEAP1 binds to its sub-
strates, and (v) a C-terminal region (CTR, amino acids 599e624).
Although there is currently no crystal structure of the full-length
KEAP1 protein, molecular modeling (Fourquet, Guerois, Biard, &
Toledano, 2010; McMahon, Lamont, Beattie, & Hayes, 2010;
Quinti et al., 2016) and multiple crystal structures of the individ-
ual BTB (Cleasby et al., 2014; Huerta et al., 2016) and Kelch (Beamer,
Li, Bottoms & Hannink, 2005; Fukutomi, Takagi, Mizushima,
Ohuchi, & Yamamoto, 2014; Komatsu et al., 2010; Li, Zhang,
Hannink, & Beamer, 2004; Padmanabhan et al., 2005) domains of
KEAP1, together with a reconstituted single particle electron mi-
croscopy structure (Ogura et al., 2010) have provided valuable
structural information on KEAP1 and the way by which it interacts
with its binding partners.
KEAP1 Substrate. The best-characterized substrate of KEAP1 is
transcription factor NF-E2 p45-related factor 2 (NRF2) (Itoh et al.,
1997, 1999). At homeostatic conditions, KEAP1 targets NRF2 for
ubiquitination and proteasomal degradation (Cullinan, Gordan, Jin,
Harper & Diehl, 2004; Kobayashi et al., 2004; Zhang, Lo, Cross,
Templeton, & Hannink, 2004). Using a mechanism known as
“hinge-and-latch” (Tong et al., 2007), one molecule of NRF2 binds
to the KEAP1 dimer via two distinct motifs residing in the N-ter-
minal Neh2 domain of the transcription factor. These are known as
the “DLG” and the “ETGE” motifs, which are situated at either side
of a central lysine-rich a-helix. The afﬁnity for the ETGE motif is
200-fold greater than that for the DLG motif, and the ETGE motif is
thought to function as the “hinge”, whereas the DLG motif func-
tions as the “latch”, positioning the NRF2 lysine-rich helix for
ubiquitination (McMahon, Thomas, Itoh, Yamamoto, & Hayes,
2006; Tong et al., 2006). The “DLG” and the “ETGE” motifs form
b-turn structures which bind via electrostatic interactions between
their acidic aspartate and glutamate residues with arginine resi-
dues 380, 415, and 483 in the Kelch domain of KEAP1. Binding to
both motifs is essential for the KEAP1-mediated ubiquitination of
NRF2 (McMahon et al., 2006) that occurs via a highly efﬁcient cyclic
mechanism (Fig. 3), in which KEAP1 is continuously regenerated
(Baird, Lleres, Swift, & Dinkova-Kostova, 2013). Chemical modiﬁ-
cation of the sensor cysteines of KEAP1 by inducers, such as sul-
foraphane, blocks the cycle of KEAP1-dependent NRF2 degradation.
This block allows de novo synthesized NRF2 to accumulate, trans-
locate to the nucleus, and initiate transcription of its downstream
Fig. 2. Metabolism of isothiocyanates in mammalian cells. The central carbon of the isothiocyanate (dN]C]S) group is electrophilic and reacts readily with sulfur-, nitrogen-,
and oxygen-centered nucleophiles. The most common reaction in mammalian cells is conjugation with sulfhydryl groups, such as the sulfhydryl group of cysteine in proteins and
glutathione. The reaction with glutathione is catalyzed by glutathione S-transferases (GSTs), and the resulting product is cleaved sequentially by g-glutamyl-transpeptidase (g-GT),
cysteinyl-glycinease (GCase), and N-acetyltransferase (NAT) to give the N-acetylcysteine conjugate (mercapturic acid). The conjugates are collectively known as dithiocarbamates.
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target genes.
Modifying KEAP1 Cysteines. By use of UV-VIS spectroscopy
cysteine modiﬁcations within KEAP1 were shown to occur when
the recombinant murine protein was incubated with sulforaphane
(Dinkova-Kostova et al., 2002). By use of mutagenesis analysis,
Zhang and Hannink found that ectopically-expressed KEAP1 in
which C151 in the BTB domain was mutated to a serine is able to
repress NRF2 even upon sulforaphane treatment, thus implicating
C151 as one of the cysteines which is speciﬁcally responsive to
sulforaphane (Zhang& Hannink, 2003). Over the subsequent years,
it became clear that C151 is one of the most reactive and critical
cysteines in KEAP1 for NRF2 signaling. McMahon and Hayes
conﬁrmed C151 as a target for sulforaphane by use of the biotin-
switch technique (McMahon et al., 2010). Additionally, molecular
modeling and mutagenesis experiments further demonstrated that
C151 is particularly highly reactive as it is spatially surrounded by
basic amino acids (H129, K131, R135, K150, and H154) which
facilitate electrophilic addition to C151. Indeed, a mutant of KEAP1
in which K131, R135, and K150 were replaced by methionine resi-
dues had a greatly reduced sensor activity. A molecular model by
Fourquet and Toledano predicted that C151 is remotely positioned
from both the BTB dimerization interface and Cullin3, and also
implicated the basic amino acid environment in the increased
reactivity of this cysteine (Fourquet et al., 2010). Based on muta-
genesis analysis, Mesecar proposed amodel whereby large residues
at position 151 cause steric clashes that lead to alteration of the
KEAP1-Cullin3 interaction, ultimately resulting in impaired ability
of KEAP1 to target NRF2 for ubiquitination (Eggler, Small, Hannink,
&Mesecar, 2009), although a crystal structure of the KEAP1 C151W
mutant BTB domain showed no obvious changes that would impact
Cullin3 binding (Cleasby et al., 2014). Mass-spectrometry ap-
proaches have shown that, depending on the experimental condi-
tions, in addition to C151, sulforaphane can also modify other
cysteines within KEAP1, including cysteines residing in the Kelch
domain (Eggler, Luo, van Breemen, & Mesecar, 2007; Hong,
Freeman, & Liebler, 2005; Hu, Eggler, Mesecar, & van Breemen,
2011). The importance of C151 in the molecular actions of sulfo-
raphane in vivo was cemented by Yamamoto and colleagues
(Takaya et al., 2012) who generated KEAP1-C151 expressing cells
from genetically engineered mice, sulforaphane evoked only mar-
ginal inductive responses in the C151 mutant cells compared to
wild-type; nuclear translocation of NRF2 and induction of its target
genes (Gclc, Nqo1) were impeded by>75%. Of note, although C151 is
the main sensor cysteine for sulforaphane, KEAP1 has other reac-
tive cysteine residues, which sense speciﬁc types of inducers
(reviewed in Dinkova-Kostova et al., 2016; Hayes & Dinkova-
Kostova, 2014). Thus C273 and C288 are modiﬁed by inducers
such as 4-hydroxynonenal and cyclopentenone prostaglandins,
whereas C434 is modiﬁed by 8-nitro-cGMP. C226 and C613 form
the sensor for metals, hydrogen peroxide and hydrogen sulﬁde.
Exogenous Modiﬁers of KEAP1 and Target Genes. Chemical
modiﬁcation of the sensor cysteine(s) of KEAP1 (by sulforaphane
and other inducers) impairs its substrate adaptor function, leading
to NRF2 accumulation and enhanced transcription of NRF2-
dependent genes. These genes have antioxidant response ele-
ments (AREs) in their upstream regulatory regions [reviewed in
(Nguyen, Nioi, & Pickett, 2009; Tebay et al., 2015)], which are the
sites of binding of NRF2 as a heterodimer with a small Maf tran-
scription factor [reviewed in (Katsuoka & Yamamoto, 2016)]. The
use of high-throughput chromatin-immunoprecipitation with
parallel sequencing methodology identiﬁed more than 600 NRF2-
target genes (Malhotra et al., 2010). NRF2-dependent genes
encode multiple functionally diverse enzymes and other proteins
with cytoprotective activities [reviewed in (Hayes & Dinkova-
Kostova, 2014; Kensler, Wakabayashi, & Biswal, 2007)]. These
include: antioxidant enzymes (e.g., heme oxygenase 1, NAD(P)
H:quinone oxidoreductase 1, thioredoxin, thioredoxin reductase, as
well as enzymes that participate in the synthesis and regeneration
of glutathione, such as the catalytic and regulatory subunits of g-
glutamylcysteine ligase, glutathione reductase); conjugating en-
zymes (e.g., glutathione S-transferases); proteins that enhance the
export of xenobiotics and/or their metabolites (e.g., solute carrier-
and ATP-binding cassette transporters); enzymes that promote the
synthesis of reducing equivalents, i.e., NADPH (e.g., glucose 6-
phosphate dehydrogenase, 6-phosphogluconate dehydrogenase,
malic enzyme 1, isocitrate dehydrogenase 1); enzymes that inhibit
inﬂammation (e.g., leukotriene B4 dehydrogenase); proteins that
protect against iron overload (e.g., ferritin, metallothionein); pro-
teins that participate in the repair and removal of damaged proteins
(e.g., subunits of the 26S proteosome) and organelles (e.g.,
autophagy-related proteins such as SQSTM1/p62, ULK1 and ATG5).
In addition, NRF2 engages in crosstalk with other transcription
Fig. 3. The cyclical model of KEAP1-mediated degradation of NRF2. (A) At homeostatic conditions, de novo synthesized NRF2 binds sequentially to the Kelch domains of the
KEAP1 dimer, ﬁrst through its high afﬁnity “ETGE” binding motif followed by the low afﬁnity “DLG” binding motif. Fully bound NRF2 is ubiquitinated and degraded through the
proteasome. Free KEAP1 is regenerated. (B) Sulforaphane blocks the cycle by chemically modifying cysteine sensor(s) of KEAP1 and disabling its substrate adaptor function.
Consequently, NRF2 is not degraded, KEAP1 is not regenerated, de novo synthesized NRF2 accumulates and, as a heterodimer with a small Maf transcription factor (sMaf), initiates
transcription of target genes.
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factors, such as the aryl hydrocarbon receptor (AhR) (Shin et al.,
2007; Yeager, Reisman, Aleksunes, & Klaassen, 2009), the retinoic
X receptor alpha (RXRa) (Wang et al., 2013), NF-kB (Nair, Doh, Chan,
Kong, & Cai, 2008), p53 (Chen et al., 2012), Notch1 (Wakabayashi,
Chartoumpekis, & Kensler, 2015; Wakabayashi et al., 2010;
Wakabayashi, Slocum, Skoko, Shin, & Kensler, 2010) and heat
shock factor 1 (Hsf1) (Dayalan Naidu, Kostov, & Dinkova-Kostova,
2015), thus inﬂuencing indirectly the expression of their respec-
tive target genes.
Nrf2 Stress Response. The networks of these NRF2-directed
transcriptional programs allow the cell to adapt and survive un-
der various conditions of stress and are at the heart of the che-
moprotective effects of NRF2 signaling. Cellular protection also
requires alterations in metabolism and bioenergetics, and although
the underlyingmechanisms are not well understood, it is becoming
increasingly clear that NRF2 activation has a profound effect on
mitochondrial function and intermediary metabolism [reviewed in
(Dinkova-Kostova & Abramov, 2015; Hayes & Dinkova-Kostova,
2014)]. Another prominent feature of NRF2 activation with high
relevance to chemoprotection is inhibition of inﬂammation.
Chronic inﬂammation and oxidative stress are the underlying
causes for most of the common human pathologies, including
cardiovascular and neurodegenerative disease, as well as cancer
(Liby & Sporn, 2012). It is the ability to suppress simultaneously
oxidative stress and inﬂammation (processes that accompany each
other and if persistent, often have deleterious effects) that makes
the activation of NRF2 signaling such a powerful and efﬁcient
protector. The broad antioxidant effects of NRF2 are largely due to
its direct transcriptional targets, which as explained earlier, include
enzymes with antioxidant activities. The anti-inﬂammatory activ-
ities of NRF2 are more complex and include transcriptional upre-
gulation of enzymes encoded by NRF2-target genes, such as
leukotriene B4 dehydrogenase (Dick, Kwak, Sutter,& Kensler, 2001;
Primiano, Li, Kensler, Trush, & Sutter, 1998), but also suppression of
the expression of genes encoding major pro-inﬂammatory cyto-
kines, such as IL-6 and IL-1b (Knatko et al., 2015; Kobayashi et al.,
2016). Finally, excessive oxidative stress and inﬂammation can
cause irreversible damage to proteins and organelles, and NRF2
activation facilitates their clearance by regulating the expression of
genes encoding multiple proteasomal subunits (Kwak & Kensler,
2006; Kwak et al., 2003) and autophagy-related proteins (Pajares
et al., 2016). In addition to direct anti-inﬂammatory effects medi-
ated through NRF2 signaling, sulforaphane may impair the redox-
sensitive DNA binding and transactivation of the pro-
inﬂammatory transcription factor NF-kB (Heiss, Herhaus, Klimo,
Bartsch, & Gerh€auser, 2001).
3. Cancer chemoprevention in animals by sulforaphane
Sulforaphane (and in a few cases broccoli sprout extracts) have
been evaluated as inhibitors of experimental carcinogenesis driven
by exposures to chemical or physical carcinogens or genetic mu-
tations. Protective efﬁcacy has been observed following adminis-
tration of sulforaphane during either the initiation or the post-
initiation stages of carcinogenesis. The initial report of the cancer
chemopreventive efﬁcacy of sulforaphane was in a model of
mammary tumor development in female Sprague-Dawley rats
treated with a single dose of the carcinogen 7, 12-dimethyl-benz-
anthracene (DMBA) (Zhang, Kensler, Cho, Posner, & Talalay, 1994).
In this study, after administration of sulforaphane by gavage (75 or
150 mmol per day for 5 days) surrounding the time of exposure to
DMBA (and a period of rapid proliferation of mammary epithelial
cells), the incidence, multiplicity, and weight of mammary tumors
were signiﬁcantly reduced, and their development was delayed.
This model was used later for evaluation of the anti-carcinogenic
action of an extract of 3-day old broccoli sprouts, which contains
the precursor of sulforaphane, glucoraphanin. Consistent with the
ﬁndings of sulforaphane, the extract of broccoli sprouts markedly
reduced the incidence and multiplicity of mammary tumors (Fahey
et al., 1997). A pharmacodynamic study in Sprague Dawley rats
demonstrated that sulforaphane could induce NQO1 transcripts,
protein and activity to a substantive degree in the mammary
epithelium (Cornblatt et al., 2007), consistent with the role of NRF2
in its protective action. Strong pharmacodynamic action reﬂecting
induction of NRF2 target genes was also observed in a bladder
cancer inhibition study in rats using lyophilized broccoli sprout
extract of known isothiocyanate content (Munday et al., 2008). A
recently developed NRF2 knockout rat (Priestley et al., 2016;
Taguchi et al., 2016) will allow direct study of the role of the
NRF2-sulforaphane connection in these models as wells as those of
NRF2 in many other physiological and pathological states.
Studies in murine models (summarized in Table 1) provide ev-
idence for the efﬁcacy of sulforaphane across stages of carcino-
genesis. The importance of NRF2 as a target for the actions of
several classes of chemopreventive agents, including sulforaphane,
was established in a series of studies conducted in wild-type and
NRF2 knockout mice (Kensler et al., 2007; Wakabayashi, & Biswal
Ramos-Gomez et al., 2001). For example, sulforaphane effectively
reduced tumor multiplicity of benzo[a]pyrene-evoked forestomach
tumors in wild-type, but not NRF2-disrupted mice (Fahey et al.,
2002). In the classic two-stage mouse skin carcinogenesis model,
by which tumors are initiated by DMBA and promoted by repeated
dosing with 12- O-tetradecanoylphorbol-13-acetate (TPA), sulfo-
raphane inhibited incidence and multiplicity of tumors during the
promotion stage (Gills et al., 2006). Xu et al. (2006) observed that
pre-treatment with sulforaphane prior to initiationwith DMBA and
subsequent promotion with TPA reduces the incidence of skin tu-
mors, when compared with the vehicle-pretreated group. Inter-
estingly, no chemoprotective effect was observed with
sulforaphane pre-treatment when NRF2-knockout mice were used.
This result supports the concept that the KEAP1-NRF2 pathway
plays an essential role in the mechanism of action of sulforaphane
against skin cancer. Sulforaphane protects wild-type mice against
oral cancer induced by treatment with 4NQO (4-nitroquinoline-1-
oxide). Parallel studies by another group using the same model
demonstrated that sensitivity to oral carcinogenesis was enhanced
in NRF2 knockout mice, whilst tumor burden was diminished in
KEAP1 knockdown mice. In SKH-1 hairless, high-risk mice, ultra-
violet (UV)-radiation-induced skin carcinogenesis was substan-
tially inhibited by topical administration of a broccoli sprout extract
containing 1 mmol sulforaphane (corresponding to ca. 50 nmol/
cm2): incidence and multiplicity were reduced by 50% in the
treatment group compared with controls (Dinkova-Kostova et al.,
2006). Feeding broccoli sprout extracts providing daily doses of
10 mmol of glucoraphanin was also protective in this model
(Dinkova-Kostova et al., 2010). Also in SKH-1 hairless mice, sulfo-
raphane treatment effectively reduced the multiplicity and tumor
burden of cutaneous squamous cell carcinomas induced by UVB
exposure (Dickinson et al., 2009). Knatko, Higgins, Fahey, &
Dinkova-Kostova (2016) found that the incidence, multiplicity
and burden of squamous cell carcinomas that form when Nrf2 is
knocked out in KEAP1 knockdown mice [Keap1(ﬂox/ﬂox)/Nrf2(/
)] are much greater than in their Keap1(ﬂox/ﬂox)/Nrf2(þ/þ)
counterparts, establishing NRF2 activation as the protection
mediator.
Another informative model is the Apcmin (adenomatosis pol-
yposis coli; multiple intestinal neoplasia) mouse, in which a
transversion point mutation introduces a stop codon that leads to
an increased burden of intestinal tumors. Several groups have
shown that treatment of Apcmin mice beginning weeks to months
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after birth with dietary sulforaphane provoked substantial re-
ductions in tumor multiplicity and overall tumor burden (Hu et al.,
2006; Myzak, Dashwood, Orner, Ho,&Dashwood, 2006; Shen et al.,
2007). To date, no studies have been conducted to examine the
effects of NRF2 genotype on tumor outcomes in this model or upon
the protective actions of sulforaphane.
4. A “dark” side to NRF2 signaling
Although activation of NRF2 signaling is generally regarded as
cytoprotective, and hence a useful target for prevention of cancer
and other diseases, cancer genome sequencing efforts have indi-
cated a substantial representation of mutations in the interaction
domains of KEAP1 and NRF2 that lead to constitutive activation of
NRF2 signaling in cancer cells (Hayes & Dinkova-Kostova, 2014;
Praslicka, Kerins, & Ooi, 2016). Thus, cancer cells frequently high-
jack the pathway to promote their survival and growth. These ac-
tions have led to controversy whether activation, or alternatively
inhibition, of NRF2 are useful strategies for the prevention or
treatment of cancer. As thoughtfully addressed by Sporn and Liby
(Sporn & Liby, 2012), the answers lie within the context of the
speciﬁc opportunities. In genetic models of pathway disruption or
hyper-activation, the “dose-response” curve is often “U”-shaped
(Kensler & Wakabayashi, 2010); pharmacological or nutritional
modulation occurs in a limited dynamic range in the middle
ground. Thus, the genetic models with constitutive activation (or
loss) of NRF2 signaling are poor mimetics or predictors of the ac-
tions of small molecule-based inducers of the pathway where
change in signaling activity is reversible and intermittent. Situa-
tions where chronic pharmacological interventions with potent
activators of NRF2 fail to phenocopy the effects of genetic consti-
tutive activation highlight this point. With regards to sulforaphane,
there is certainly a continuing need for the monitoring of safety
with long-term administration in pre-clinical models as well as
clinical trials. Nonetheless, prolonged treatment with sulforaphane
did not enhance tumorigenesis in oncogenic K-ras and xenograft
mouse models of lung cancer (Kombairaju et al., 2011), whilst ge-
netic modulation of NRF2 state has been shown to affect lung
carcinoma development (Jeong et al., 2017; Satoh, Moriguchi, Takai,
Ebina, & Yamamoto, 2013).
5. Demonstrating pharmacodynamic action of sulforaphane
in humans: NRF2 signaling as a probe
There is considerable interest in developing small molecules
that activate the NRF2 signaling pathway in humans for prevention
Table 1
Chemopreventive Activity of sulforaphane in mice: Modulation by Nrf2.
Organ
site
Species
strain
Carcinogen/
mutation
SFN Formulation or dose Endpoints measured Reference
Wild-type vs. NRF2-knockout mice
Skin Mouse \
C57Bl6
DMBA 100 nmol SFN, topical, q.d. X 14 before DMBA Reduced tumor incidence in WT with SFN, but not NRF2 KO
mice
Xu et al., 2006
Stomach Mouse \
C57Bl/6
4NQO 7.5 mmol SFN q.d. X 9 before/after B[a]P Reduced tumor incidence in WT with SFN, but not NRF2 KO
mice
Fahey et al.,
2002
Colon Mouse \
C57Bl/6J
4NQO 400 ppm SFN in the diet Reduced tumor multiplicity and burden in WT mice with SFN;
NRF2+/- mice less sensitive than WT mice & no protection by
SFN
Rajendran et
al., 2015
Oral Mouse \
C57Bl/6
4NQO 6 mmol SFN/mouse; 3X wk, p.o. for 16 wk SFN protects WT at 24 wks Bauman et al.,
2016
Mouse \
C57Bl/6J
4NQO No treatment NRF2 KO more sensitive: KEAP1-KD more resistant than WT at
24 wks
Ohkoshi et al.,
2013
Skin Mouse \
SKH-1
UV 100 mL broccoli sprout extract containing 1 mmol SFN
topical
Reduced tumor incidence, multiplicity & burden Dinkova-
Kostova et al.,
2006
Mouse \
SKH-1
UV broccoli sprout extract providing 10 mmol
glucoraphanin daily in the diet
Reduced tumor incidence, multiplicity & burden Dinkova-
Kostova et al.,
2010
Mouse \
SKH-1
UV No treatment NRF2 KO much more sensitive than KEAP1-KD Knatko et al.,
2016
Wild-type rodents only
Skin Mouse \
CD-1
DMBA/
TPA
1, 5 or 10 mmol SFN topical before TPA Reduced tumor incidence & multiplicity Gills et al.,
2006
Skin Mouse \
SKH-1
UV 2.5 mmol SFN topical Reduced tumor incidence & multiplicity Dickinson et
al., 2009
Colon Mouse _
C57Bl/6J+/
min
Apcmin ~6 mmol SFN/d (443 ppm) in diet for wks 6e16 Reduced tumor multiplicity Myzak et al.,
2006
Colon Mouse Apcmin 300 or 600 ppm SFN in diet for wks 8e11 Dose-dependent reduction in tumor multiplicity Hu et al., 2006
Colon Mouse _ Apcmin 600 ppm SFN in diet for wks 5e15 Reduced tumor multiplicity Shen et al.,
2007
Lung Mouse \
A/J
B[a]P + NNK 3mmol/kg; 20 wks after carcinogen administration, fed
diet containing SFN wks 21e42.
Reduced tumor incidence Conaway et
al., 2005
Prostate Mouse _ TRAMP 6 mmol SFN/mouse; 3X wk, p.o. for 17e19 wk Reduced tumor incidence Singh et al.,
2009
Prostate Rat _ TRAMP 60 and 240 mg broccoli sprouts/mouse/day, p.o., for
16 wk
Reduced tumor incidence Keum et al.,
2009
Bladder Rat \ BBN lyophilized broccoli sprout extract in diet to provide
isothiocyanate doses of 40 and 160 mmol/kg body
weight/d
Reduced tumor incidence, multiplicity and size Munday et al.,
2008
Abbreviations: KO, knockout, KD, knockdown; WT, wild-type; SFN, sulforaphane; DMBA, dimthylbenz[a]anthracene; TPA, 12-O-tetradecanoylphorble ester; 4NQO, 4-
nitroqquinoline-1-oxide); UV, ultraviolet light; B[a]P, benzo[a]pyrene; AOM, azoxymethane; DMH, dimethylhydrazine; N-OH-BBN, N-butyl-N-(4-hydroxybutyl) nitrosamine;
TRAMP, transgenic adenocarcinoma of mouse prostate; NNK: 4-(methylnitrosamino)-1-(3-pyridyl)e1-butanone.
A.T. Dinkova-Kostova et al. / Trends in Food Science & Technology 69 (2017) 257e269262
and treatment of multiple acute and chronic diseases. One such
drug, tecﬁdera (dimethylfumarate) was approved by the FDA in
2012 for treatment of relapsing multiple sclerosis. The oleanane
triterpenoid bardoxolone methyl is used in clinical trials for treat-
ment of chronic kidney disease and pulmonary arterial hyperten-
sion. ClinicalTrials.gov lists over a score of trials using “broccoli” or
“sulforaphane” in multiple disease settings including asthma,
autism, schizophrenia, cystic ﬁbrosis, sickle cell, alcohol intoler-
ance, cardiovascular disease, immune response to inﬂuenza,
dermatitis and cancer prevention. Published results from such trials
were reviewed in 2015 (Conzatti, Froes, Schweigert Perry, & Souza,
2015).
Among many challenges in the design and implementation of
such trials are the selection of an adequate dose, type of formula-
tion and dose schedule. Biomarkers, tools for the assessment of
pharmacodynamic action of sulforaphane, are extremely useful in
this regard. While there has been considerable progress in char-
acterizing the pharmacokinetics of various broccoli/sulforaphane
preparations (Atwell et al., 2015a, b; Egner et al., 2011; Fahey et al.,
2012b) and improved formulations with which to provide more
consistent bioavailability (Fahey et al., 2015), there is limited evi-
dence for target modulation in humans, be it the putative target
NRF2 or something else. Three general approaches have been uti-
lized. 1. Examination of the serum secretome; 2. gene expression
changes in peripheral blood mononuclear cells or other accessible
cells (e.g., skin or buccal cells or nasal swabs); and 3. altered “drug”
metabolism phenotypes. There have now been many clinical
studies that have utilized either orally or topically (skin surface)
delivered sulforaphane (Table 2). Delivery vehicles range from fresh
broccoli or broccoli sprouts to commercial nutritional supplements
containing glucoraphanin or stabilized sulforaphane, to custom
preparations that are highly enriched in these phytochemicals but
may never be suitable for large populations. Many of the studies
have used a dried extract of broccoli sprouts or seeds. Unfortu-
nately, whereas many clinical studies have chemically character-
ized the preparations used, and have used standardized
preparations (reviewed by: Fahey & Kensler, 2007; Fahey et al.,
2012a), others have not. In addition to purely pharmacokinetic
evaluations which we do not address herein, many of the clinical
studies summarized in Table 2 have gone beyond KEAP1-NRF2-ARE
related outcomes and examined outcomes or biomarkers related to
some of sulforaphane's other modes of action (e.g. antibiosis, anti-
inﬂammatory). These may or may not involve cross-talk with the
NRF2 pathway and thus may be of interest in the context of this
review.
Feeding studies with cruciferous vegetables, presumably rich in
isothiocyanates, have demonstrated increased circulating levels of
NRF2 target gene products (e.g., GST, NQO1), measured as proteins
or enzymatic activities. Bogaards (Bogaards, Verhagen, Willems,
van Poppel, & van Bladdern, 1994) reported in a clinical study,
small but signiﬁcant increases in plasma levels of a-class GST were
observed in volunteers consuming a diet enriched in Brussels
sprouts. Navarro (Navarro et al., 2009) similarly demonstrated
modulation of human serum GSTA1/2 concentration by cruciferous
vegetables in a controlled feeding study. Sreerama (Sreerama,
Hedge, & Sladek, 1995) reported increased enzymatic activity of
GSTs and NQO1 in the saliva of subjects who continually ingested
large quantities of broccoli. In no cases were content of sulfo-
raphane or other isothiocyanates measured in the dietary vegeta-
bles used. Other proteins show larger dynamic range of induction
through NRF2 activation (e.g., AKRs); while increased concentra-
tions have been observed in the media of cells following treatment
with sulforaphane (Agyeman et al., 2012), they have not been
examined in clinical samples. Increased annotation of the human
serum secretome coupled with deeper interrogation with new
mass spectrometric methods offers prospects for the identiﬁcation
of secreted, circulating proteins reﬂecting the pharmacodynamic
action of sulforaphane in clinical trial settings. In a similar vein,
metabolomics surveys of bioﬂuids may provide candidate markers
exhibiting sufﬁcient abundance, speciﬁcity and dynamic range in
response to changes in signaling ﬂux through the NRF2 pathway.
Elevated levels of gene transcripts for NRF2 target genes such as
NQO1 and GSTs have been reported in healthy volunteers following
administration of broccoli-based glucoraphanin/sulforaphane
preparations in skin punch biopsies, nasal scrapings, buccal scrap-
ings, peripheral blood mononuclear cells, and whole blood collec-
tions for isolation of mRNA (Bauman et al., 2016; Brown, Reynolds,
Brooker, Talalay, & Fahey, 2015; Doss et al., 2016; Dinkova-Kostova
et al., 2007; Riedl, Saxon, & Diaz-Sanchez, 2009). These studies
signal the likely activation of the NRF2 pathway in these cell types,
but optimization of dose, formulation, timeframe and tissue pro-
cessing have not been undertaken rigorously to date. Additionally,
studies to link the magnitude of change in expression of marker
genes with more functional endpoints have not been conducted.
Pharmacologic manipulations and crucifer-rich diets have been
shown to modify the “phase 2” or conjugation metabolism of
antipyrine, phenacetin, oxazepam, and acetaminophen in humans
(Pantuck et al., 1979; Park & Kitteringham, 1990). Rather than using
drugs to monitor phenotypic changes in metabolic pathways as
done in these early studies, we have relied e and in fact targeted e
environmental exposures to food and airborne carcinogens with
the purposeful intention of increasing rates of their detoxication
with broccoli-based interventions.
In a 2009 cross-over clinical trial conducted in Qidong, China, in
which 50 healthy subjects were recruited to take two broccoli
sprout-derived beverages: one glucoraphanin-rich (GRR) and the
other sulforaphane-rich (SFR), the pharmacodynamic actions of
these two beverages were compared (Kensler et al., 2012). Urinary
excretion of the mercapturic acids of the air-borne toxins acrolein,
crotonaldehyde, ethylene oxide, and benzene were measured in
urine samples from both pre- and post-interventions using liquid
chromatography tandem mass spectrometry. Statistically signiﬁ-
cant increases of 20%e50% in the levels of excretion of glutathione-
derived conjugates of acrolein, crotonaldehyde and benzene were
seen in individuals receiving SFR, GRR, or both compared with their
pre-intervention baseline values. No signiﬁcant differences were
seen between the effects of SFR versus GRR on the pollutant
biomarker levels. In a more recent 12-week placebo-controlled,
randomized clinical trial, in which 291 participants from Qidong
were provided a broccoli sprout beverage containing both 40 mmol
sulforaphane and 600 mmol glucoraphanin, the urinary levels of the
mercapturic acids of the air pollutants, benzene, and acrolein were
measured and used as biomarkers of health risk. The detoxiﬁcation
of these airborne pollutants was enhanced by the broccoli sprouts
beverage. The levels of excretion of the glutathione-derived con-
jugates of benzene (61%) and acrolein (23%) were signiﬁcantly
higher in the participants who received the broccoli sprout
beverage compared with placebo. This increase in pollutant-
mercapturic acid excretion was rapid and sustained throughout
the intervention (Chen et al., 2012). Overall, this study provided
strong evidence that broccoli sprout beverage can modulate the
disposition of environmental carcinogens and toxins. The role of
NRF2 in these actions is not established but inferred as inﬂuences of
polymorphisms in GST isoforms and in the promoter region of
NRF2 itself on the rates of detoxication of benzene were noted.
6. KEAP1 and done?
By no means is this so. Many complex diseases have proven
historically to be resistant to mono-preventive or therapeutic
A.T. Dinkova-Kostova et al. / Trends in Food Science & Technology 69 (2017) 257e269 263
Table 2
Modulation of NRF2 targets in clinical studies with broccoli preparations.
Agent Dose and Schedule Sample Size
(duration)
aBiomarker Modulation References
Studies demonstrating an NRF2-related pharmacodynamic effect
Broccoli Sprout
Beverage
(GRR)
C7Placebo, q.d.
C400 mmol GRR q.d.
200
(14 days)
9% decrease in urinary excretion of AFB-N7-gua DNA adducts at 10 days; 10%
decrease in pollutant PheT excretion
Kensler et al.,
2005
Broccoli Sprout
Extract
(SFR)
C5, 40, 170 or 340 nmol
sulforaphane-rich BSE applied
topically once
17
(1 dose)
Increased NQO1 activity (> 1.5-fold) in skin punch biopsies 24 h after topical
application of 170 or 340 nmol SFN containing BSE
Dinkova-Kostova
et al., 2007
Broccoli Sprout
Extract
(SFR)
C50, 100, 150, or 200 nmol
sulforaphane-rich BSE applied
topically, 3 times
17
(3 doses,
every 24 h)
Dose-dependent increase in NQO1 activity (up to 4.5-fold) in skin punch biopsies
24 h after the last dose
Dinkova-Kostova
et al., 2007
Broccoli Sprout
Extract
(SFR)
C200 or 400 nmol sulforaphane-rich
BSE applied topically, 3 times
6
(3 doses,
every 24 h)
Yerythema (by ~40%) on 5th day, from narrow band UVB (340 nm) irradiation on
4th day, following SF- compared to solvent-treatment
Talalay et al.,
2007
Broccoli Sprout
Homogenate
(SFR)
C25, 50, 75, 100, 125, 150, 175, 200 g
broccoli sprout homogenate (BSH)
C200 g alfalfa sprout homogenate
(ASH)
q.d.
57
(3 days)
Doubling (GSTP) or tripling (NQO1) of gene transcripts in nasal lavage after 3
doses of 200 g (102 mmol) BSH but not ASH.
Riedl et al., 2009
Broccoli Sprout
Homogenate
(SFR)
C200 g broccoli sprout homogenate 12
(3 days)
Signiﬁcant increase in protein levels of secretory leukocyte protease inhibitor in
nasal lavage after 48 h.
Meyer et al.,
2013
Broccoli Sprout
Beverage
(GRR4 SFR)
Cross-over
CRun-in/ GRR (800 mmol)/
wash-out/ SFR (150 mmol)
CRun-in/ SFR/wash-out/ GRR
50
(24 days)
20e50% increases in urinary excretion of mercapturic acid conjugates of air
pollutants: acrolein, ethylene oxide, crotonaldehyde, benzene
Kensler et al.,
2012
Broccoli Sprout
Beverage
GRR + SFR
Blend
CPlacebo
CGRR (600 mmol) +CSFR (40 mmol)
291
(84 days)
Rapid and sustained increases in the rate of urinary elimination of mercapturic
acids of benzene (61%) and acrolein (23%), but not crotonaldehyde
Egner et al., 2014
Broccoli Sprout
Homogenate
(SFR)
CSFR (100 mmol) 45
(14 days)
Positive association between increased FEV1 response to methylcholine and
induction of GCLM and NQO1 transcripts in peripheral blood mononuclear cells
in response to sulforaphane.
Brown et al.,
2015
Broccoli Sprout
Extract (BSE)
(GRR capsule)
CPlacebo
CBSE capsules [10 mg GR ea.
(23 mmol)]
3 capsules q.d.
52
(96 days)
Signiﬁcant reduction in urinary excretion of 8-OHdG compared to placebo. Kikuchi et al.,
2015
Broccoli Sprout
Extract (SFR)
CSingle (200 mmol) & dual
(100 mmol, q12h)
20
(1 day)
No induction of HO-1 observed; transient decrease in HDAC activity observed at
3 h post dosing
Atwell et al.,
2015a
Broccoli Sprout
Extract (BSE)
(GRR capsule)
CBSE capsules [10 mg GR ea.
(23 mmol)]
3 or 6 capsules q.d.
21
(3 days)
Dose dependent increases in serum enzyme activities of GST (CDNB) and NQO1. Ushida et al.,
2015
Broccoli Sprout
Beverages
(GRR or SFR)
CSingle arm crossover
GRR (600 mmol)/
SFR (40 mmol)
10
(5 days)
Induction of NQO1 transcripts in buccal cells scraped from inner cheek with GRR
or SFR beverages compared to run-in.
Bauman et al.,
2016
Broccoli Sprout
Homogenate
(SFR)
C50e150 mmol dose escalation 14
(21 day trt +
28 day
washout)
Increase in whole bloodmRNA for HMOX1 and trend for samewith HBG1 but no
sig D in HbF, in sickle cell disease (SCD) patients.
Doss et al., 2016
Broccoli Sprout
Homogenate
C200 g BSHCPlacebo¼ 200 g alfalfa
sprout homogenate
15
(3 days)
No increased expression of NRF2-regulated gene transcripts (GSTM1,
HO-1, NQO1, NRF2) in nasal epithelial cells or peripheral blood. No decrease in %
PMNs in sputum following O3 challenge.
Duran et al., 2016
Studies demonstrating an effect that is not [necessarily] NRF2-related
Fresh BS C100 g fresh wt. BS (~600 mmol GR) 12
(7 days)
YPCOOH, Y8OHdG, Y8iso, [CoQ, [HDL-C (\ only) Murashima et al.,
2005
Fresh BS C318e1271 mmol GR 9
(7 days)
Subjects e H. pylori infected:
7 of 9 appeared “cured”; between 2 and 6 still cured after 35 days
Galan et al., 2004
Cooked B
(Hi- and Low-
GR soup)
C344 and 102 mmol GR 16
(1 day /single
dose)
[regulation of various genes involved in xenobiotic metabolism, including those
assoc. with NRF2 pathway (e.g. AKR, GCLM) and the heat shock pathway
Gasper et al.,
2007
Fresh BS C68 g BS (~593 mmol SF) 3
(21 days)
YHDAC in PBMCs and [acetylated histones H3&H4 at 3& 6 h post consumption Myzak et al.,
2007
Fresh BS or BS
supplements
C68 g BS or 6 pills of supplement
(~3 g of freeze dried BS)
24
(7 days)
YHDAC in PBMCs at 12 and 48 h after the ﬁnal dose of sprouts or supplement Clarke et al., 2011
Steamed B CPlacebo (400 g peas per week)
C400 g B per week
22
(1 year)
D inmRNA processing, TGFb1, IL-2, NOTCH,WNT, EGFR1, and insulin signaling in
prostate needle biopsies
Traka et al., 2008
Fresh BS CPlacebo
C420 mmol GR
50
(54 days)
Subjects e H. pylori infected: Considerable YH. pylori infection, and Ypro-
inﬂammatory markers, YUBT, but no complete eradication
Yanaka et al.,
2009
BSE (GR) C200 mmol GR-rich BSE, orally 4
(single dose)
Yinactivation (by >95%) of macrophage migration inhibitory factor (MIF)
tautomerase activity in urine 8 h after dosing
Healy et al., 2011
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approaches. Mechanisms for resistance can be many-fold, and in
addition to factors affecting the pharmacokinetics of the molecule,
loss or alteration in the primary molecular target can become a
substantive barrier to efﬁcacy. As highlighted in this review, there is
ample evidence that sulforaphane, administered in a variety of
broccoli-based formulations e or as pure compound to animals e
can activate the KEAP1-NRF2 signaling pathway. What is less clear
is whether this pathway is the primary target (i.e., preferentially
affected at the lowest concentrations). Very few dose-response
studies have been conducted in humans, animals, or even cell
culture systems that provide much guidance of the hierarchy of
sulforaphane interactions with cysteine-rich targets, be it KEAP1 or
other proteins (or indeed that cysteine residues are the only
chemical targets, e.g., lysine). A potential attraction for the use of
sulforaphane, in addition to the profound feasibility of developing
practical, effective broccoli-based formulations for administration,
is the possibility that multiple pathways are perturbed and that in
toto, such actions provide stronger opportunities for disease pre-
vention or treatment. As exempliﬁed in the studies listed in Table 2,
sulforaphane canmodulate other signaling pathways and biological
processes underlying the etiopathogenesis of complex disease
states. Continued evaluation of the pharmacokinetics and phar-
macodynamic action by tracking the actions of sulforaphane on the
KEAP1-NRF2 stress response system provides one means to opti-
mize the development of intervention strategies and to match the
intervention to the appropriate at-risk populations. However, it is
only one guidepost on the trail to effective, frugal disease
mitigation.
Table 2 (continued )
Agent Dose and Schedule Sample Size
(duration)
aBiomarker Modulation References
BSP (SFR) Cplacebo
C112 mmol SFb
C224 mmol SFb
81
(28 days)
Subjects - with type 2 diabetes:
Yinﬂammatory markers in high SF group compared with placebo
Yfasting glucose, total cholesterol & LDL levels in both groups: no
effect on insulin sensitivity
Ymalondialdehyde
Mirmirin et al.,
2012
Bahadoran et al.,
2011; 2012a;
2012b
Blanched,
Frozen B
CPlacebo (peas)
CHigh GR B (21.6 mmol/g dry wt.)
CLow GR B (6.9 mmol/g dry wt.)
48
(84 day)
Biomarkers of CVD risk;
Yvariation in lipid and a.a. metabolites and TCA cycle intermediates suggesting
altered control points
Armah et al.,
2013
BSE (SFR) 450 mmol SF/day delivered in cheese-
based soup
CSF,
CSF+RIF,
CRIF (rifampicin)
24
(7 days x 3)
Subjects e healthy volunteers characterized for CYP3A4 status:
SF treatment did not affect CYP3A4 activity
Poulton et al.,
2013
BSP (SFR) CStandard triple therapy
CBSP (135 mmol SF/d)b
CBSP + triple therapy
86
(28 days)
Subjects e type 2 diabetes / H. pylori infected patients:
Considerable YH. pylori infection, and Ypro-inﬂammatory markers, but no
complete eradication
Bahadoran et al.,
2014
BSE (SFR) C100 mmol SF/d delivered in mango
juice
29
(4 days BSE
trtmnt)
Subjects challenged with an irritation/allergy-provoking diesel exhaust particle
(DEP) suspension; white blood cell counts declined by 54% when DEP challenge
was preceded by daily BSE admin for 4 days
Heber et al.,
2014a, b
BSE (SFR) C200 mmol SF/d 20
(140 days)
Subjects e men with biochemical recurrence of prostate cancer:
PSA doubling time was 9.6 mo. on-trtmnt, vs. 6.1 mo. pre-trtmnt; 1 subj had
>50% YPSA; 7 subj had 50% declines; (no placebo group)
Alumkal et al.,
2015
B (Blanched,
Frozen)
CHigh GR B (21.6 mmol GR/g dry wt.)
CLow GR B (6.9 mmol GR/g dry wt.)
37
(84 days)
Subjects - w/ elevated CVD risk: Measured blood lipid markers in;
Found YLDL-C w/ High GR B
No sig diff in TC, HDL-C, TAG
[Study 1]
Armah et al.,
2015
[Study 2]
CHigh GR B (24.8 mmol GR/g dry wt.)
CLow GR B (9.5 mmol GR/g dry wt.)
96
(84 days)
BSdE (GRR) 2 pills, 3x/d:
Cplacebo
C514 mmol GR/d
54
(56 days)
Subjects - breast biopsy candidates:
YKi67, YHDAC3 in benign tissue, YHDAC in PBMCs
Atwell et al.,
2015b
BSdE (SFR) Cplacebo
C339 mmol SF/day in tablets for
6 mo., followed by 2 mo. non treated
follow-up
78
(182 days)
Subjects e radical prostatectomy patients:
PSA doubling time was 86% longer in SF than placebo group (28.9 & 15.5 months
respectively). SF effects prominent at 3 mo. and maintained throughout
Cipolla et al.,
2015
BSE (SFR) C200 mmol SF-rich, or
C200 mmol GR-rich BSE, applied
topically daily  3 d
24
(5 days)
Yerythema on 5th day, from solar simulated UV irradiation on 4th day, following
SF- but not GR-treatment
Knatko et al.,
2015
BSdE (GR) Daily, 3 oral tablets delivering:
C69 mmol GR
10
(54 days)
Subjects - shizophrenia outpatients:
PANSS & CGI (cognitive function tests) showed suggestion of improvement;
serum BDNF (nsd)
Shiina et al., 2015
BSE (SFR) C50 mmol SF
C100 mmol SF
C200 mmol SF
17
(28 days)
Subjects e w/ melanoma & multiple atypical/dysplastic nevi:
Ds in pSTAT3 (nsd); Ypro-inﬂamm factors (nsd); & Ytumor suppressor decorin
Kirkwood et al.,
2016
Fresh BS CPlacebo
C100 g BS
40
(3 days)
Subjects e asthmatics w/ pos. skin test to indoor allergen:
No differential effect on asthma-related endpoints including NRF2-related; no
measurement of actual dose (SF or GR)
Sudini et al., 2016
Fresh BSH CPlacebo
C100 mmol SF
29
(21 days)
Subjects innoc. w/ FluMist LAIV (Live Attenuated Inﬂuenza Virus):
[peripheral blood NK cell expression (granzyme B production) & Ycirculating
inﬂuenza RNA
Müller et al.,
2016
Abbreviations: 8iso, 8-isoprostane; 8OHdG, 8-hydroxy 20-deoxy guanosine; AFB-N7-gua, aﬂatoxin B1-N7-guanine; ASH, alfalfa sprout homogenate; B, broccoli; BS, broccoli
sprouts; BSdE, broccoli seed extract; BSE, broccoli sprout extract; BSH, broccoli sprout homogenate; BSP, broccoli sprout powder; CoQ, CoQ10H2/CoQ10 ratio; CVD, cardio-
vascular disease; GR, glucoraphanin; GRR, glucoraphanin-rich; HDL-C, High Density Lipoprotein e Cholesterol; LDL-C, Low Density Lipoprotein e Cholesterol; nsd, no sig-
niﬁcant difference; PANSS, positive and Negative syndrome scale; PCOOH, phosphatidylcholinyl hydroperoxide; PheT, phenanthrene tetraol; SFN, sulforaphane; SFR,
sulforaphane-rich; TAG, triglycerides; TC, total cholesterol; TTR, transthyretin; ZAG, zinc a-2 glycoprotein.
a Subjects were healthy unless otherwise indicated at the beginning of these sections.
b Nominally designated at SF-rich, but it is clear that the SF titer of these powders is not as advertised and the investigators did not do further analysis of GR or SF titer.
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